Avycaz is a combination antibiotic consisting of ceftazidime, a cephalosporin, and avibactam, a beta-lactamase inhibitor.
The updates include a primer on HCV resistance and guidance on treating patients who have undergone kidney transplantation.
The researchers found that the overall rate of SSI was 10.9% in the cohort. Overall, 6.4 and 15.4% of women in the cephalexin-metronidazole and placebo groups, respectively, were diagnosed with SSI (relative risk, 0.41).
The study authors reported that of the 11,932 infants exposed to HIV, 5780 (48.4%) of them were considered ART exposed from conception.
While the first year after infection has the highest risk (adjusted hazard ratio [aHR], 6.33), an increased risk persists for the second (aHR, 2.47) and third year (aHR, 2.12) after infection.
The investigation found that that the nurse had replaced the active medication with saline or another solution. All of the patients recovered except one who died from a sepsis infection.
Beyond the conclusion that 2 doses were just as protective as 3, the researchers found that both dose regimens offered much more protection against genital warts than a single dose or no vaccine at all.
By using the Centers for Disease Control and Prevention (CDC) HIV surveillance data, researchers were able to project yearly estimates of new infections and forecast the route of HIV in the U.S.
In fact, a 20-year-old with HIV who began antiretroviral treatment in 2008 or later and had a low viral load after a year of treatment has a life expectancy that's close to that of the general population.
The analysis found treatment with Livalo led to a statistically significant and superior reduction in LDL-C vs. pravastatin at Week 12.
Results showed that compared with current use of metformin + sulfonylurea, the use of thiazolidinediones + metformin was associated with an increased risk of CAP.
Results were in line with previous studies which showed an patients achieving a mean reduction in viral load of 1.6 log10 over a 24 week treatment period.
Janssen announced positive data from the SWORD Clinical Trial Program of the two-drug regimen dolutegravir (ViiV Healthcare) and rilpivirine (Janssen) for the maintenance treatment of HIV-1 infection in patients who have already achieved viral suppression.
AbbVie announced the submission of a New Drug Application (NDA) for the pan-genotypic regimen of glecaprevir/pibrentasvir being developed for the treatment of chronic hepatitis C virus (HCV).
Data from the Birth Defects Study found that influenza vaccination coverage rose during the 2012-13 and 2013-14 season from 35% to 41%, respectively.
The Centers for Disease Control and Prevention (CDC) issued the final report on the Winnable Battles program which highlights public health priorities with large-scale impact on health and strategies that may help to address them.
The Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Kaletra (lopinavir/ritonavir; AbbVie) film-coated tablets and oral solution.
The Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Norvir (ritonavir; AbbVie) 80mg/mL oral solution, 100mg tablets and 100mg soft-gel caps.
A study published in JAMA reports that anticoagulants, antibiotics, diabetes drugs, and opioids are the most common drug classes related to emergency department visits for adverse drug events in the country.
GlaxoSmithKline announced that the Food and Drug Administration (FDA)'s Center for Biologics Evaluation and Research has approved an expanded indication for FluLaval Quadrivalent (influenza vaccine) to include the use in children aged ≥6 months.
Researchers aimed to compare the risk of pneumonia with the use of donepezil, oral rivastigmine, transdermal rivastigmine, galantamine, and memantine.
For infants with congenital Zika syndrome (CZS), Zika virus (ZIKV) can cause retinal damage, which can be seen on optical coherence tomography (OCT), according to a study published online in JAMA Ophthalmology.
Animal research with an experimental two-drug therapy could hold clues for creating long-term HIV remission, according to a report published online November 9 in Nature.